Rituximab is an anti-CD20 chimeric monoclonal antibody that depletes CD20-expressing B cells. Rituximab is used in a broad range of conditions, including cancer, rheumatologic conditions, and primary immunodeficiency. Current US Food and Drug Administration–approved indications include non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
1 In addition, there are many off-label uses in other specialties
2 and expanding indications for rituximab in common variable immunodeficiency (CVID)
3 and ongoing combination therapy trials.
4